1. Home
  2. LEXX vs HTCR Comparison

LEXX vs HTCR Comparison

Compare LEXX & HTCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEXX
  • HTCR
  • Stock Information
  • Founded
  • LEXX 2004
  • HTCR 2009
  • Country
  • LEXX Canada
  • HTCR Japan
  • Employees
  • LEXX N/A
  • HTCR N/A
  • Industry
  • LEXX Biotechnology: Pharmaceutical Preparations
  • HTCR EDP Services
  • Sector
  • LEXX Health Care
  • HTCR Technology
  • Exchange
  • LEXX Nasdaq
  • HTCR Nasdaq
  • Market Cap
  • LEXX 22.7M
  • HTCR 18.9M
  • IPO Year
  • LEXX N/A
  • HTCR 2022
  • Fundamental
  • Price
  • LEXX $1.06
  • HTCR $0.84
  • Analyst Decision
  • LEXX Strong Buy
  • HTCR
  • Analyst Count
  • LEXX 1
  • HTCR 0
  • Target Price
  • LEXX $4.00
  • HTCR N/A
  • AVG Volume (30 Days)
  • LEXX 283.7K
  • HTCR 2.6M
  • Earning Date
  • LEXX 11-25-2025
  • HTCR 11-13-2025
  • Dividend Yield
  • LEXX N/A
  • HTCR 15.48%
  • EPS Growth
  • LEXX N/A
  • HTCR N/A
  • EPS
  • LEXX N/A
  • HTCR N/A
  • Revenue
  • LEXX $615,923.00
  • HTCR $29,625,381.00
  • Revenue This Year
  • LEXX $46.98
  • HTCR N/A
  • Revenue Next Year
  • LEXX $17.26
  • HTCR $3.52
  • P/E Ratio
  • LEXX N/A
  • HTCR N/A
  • Revenue Growth
  • LEXX 49.85
  • HTCR 72.95
  • 52 Week Low
  • LEXX $0.77
  • HTCR $0.39
  • 52 Week High
  • LEXX $2.85
  • HTCR $3.38
  • Technical
  • Relative Strength Index (RSI)
  • LEXX 56.87
  • HTCR 53.19
  • Support Level
  • LEXX $0.99
  • HTCR $0.78
  • Resistance Level
  • LEXX $1.21
  • HTCR $0.86
  • Average True Range (ATR)
  • LEXX 0.08
  • HTCR 0.07
  • MACD
  • LEXX 0.02
  • HTCR 0.01
  • Stochastic Oscillator
  • LEXX 58.97
  • HTCR 72.85

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.

About HTCR Heartcore Enterprises Inc.

HeartCore Enterprises Inc is a software development company. The company provides software through two business units. The first business unit includes a customer experience management business. The customer experience management platform includes marketing, sales, service, and content management systems, as well as other tools and integrations that enable companies to attract and engage customers throughout the customer experience. It also provides education, services and support to help customers be successful with the CXM Platform. The second business unit, DX division, is a digital transformation business that provides customers with robotics process automation, process mining, and task mining to accelerate the digital transformation of enterprises.

Share on Social Networks: